- alfapump® – successful primary endpoint read-out of North American pivotal POSEIDON study / PMA filing planned for H2 2023
- DSR® (Direct Sodium Removal) – clinical evidence of disease-modifying heart failure drug therapy, on track to start US Phase 1/2a MOJAVE study in Q2 2023
- Total cash position of €18.9 million at end 2022 and cash runway into mid-2023
Conference call with live webcast today at 03:00 pm CEST / 09:00 am EST
Ghent, Belgium – 09 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces its financial results for the year ended 31 December 2022, and provides a business update and outlook for 2023.